Salih Zeki Guclu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Salih Zeki Guclu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Enriqueta Felip
Vall d’Hebron University Hospital, Barcelona, Spain
5 shared publications - Erdem Göker
Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
4 shared publications - Glenwood D. Goss
Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada
4 shared publications - Manuel Cobo
Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain; IBIMA Plataforma BIONAND, Málaga, Spain
4 shared publications - Shirish M. Gadgeel
Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI
4 shared publications - Alessandro Morabito
Thoracic Medical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, 80131 Napoli, Italy
3 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Lymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Open AccessLymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- 1 December 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, ix143-ix144
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
- 1 December 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, ix143-ix144
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA265
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial
Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. This phase III trial prospectively compared A and E in pts with SCC of the lung following failure of platinum-based first-line chemotherapy. Methods: Pts with stage IIIB/IV SCC were randomized 1:1 to receive A (40 mg/day; n=335) or E (150 mg/day; n=334) until progression. The primary endpoint was PFS. Secondary endpoints were OS, ORR, DCR, patient-reported outcomes (PROs) and safety. Results: Baseline characteristics were well balanced between arms. Median PFS was significantly higher for A than E (2.4 vs 1.9 mths; HR [95% CI]: 0.82 [0.68–1.00]; p=0.04). Also, ORR (4.8 vs 3.0%; p=0.23) and DCR (45.7 vs 36.8%; p=0.02) were higher with A vs E. Overall AE profile was comparable (≥G3 AEs: 50.2 and 49.1%, serious AEs: 39.2 and 38.0% for A and E, respectively) with higher incidence of drug-related ≥G3 diarrhoea (9.7 vs 2.4%) and G3 stomatitis (3.3 vs 0%) with A and higher incidence of G3 rash/acne with E (5.5 vs 9.0%). AEs leading to treatment discontinuation were comparable (17.9 vs 13.9%). More pts had improved global health status/quality of life (36.4 vs 27.1%; p=0.03) with A than E. Changes in mean scores over time significantly favoured A vs E for cough, dyspnoea and pain. Primary OS, updated PFS, response and PRO data will be presented at the meeting. Conclusions: LL8 is the largest prospective trial comparing A vs E, an approved TKI in pts with pretreated SCC. PFS, DCR and improved global health status were significantly better for A than E. AEs were comparable and manageable.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , OA265
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial
Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. This phase III trial prospectively compared A and E in pts with SCC of the lung following failure of platinum-based first-line chemotherapy. Methods: Pts with stage IIIB/IV SCC were randomized 1:1 to receive A (40 mg/day; n=335) or E (150 mg/day; n=334) until progression. The primary endpoint was PFS. Secondary endpoints were OS, ORR, DCR, patient-reported outcomes (PROs) and safety. Results: Baseline characteristics were well balanced between arms. Median PFS was significantly higher for A than E (2.4 vs 1.9 mths; HR [95% CI]: 0.82 [0.68–1.00]; p=0.04). Also, ORR (4.8 vs 3.0%; p=0.23) and DCR (45.7 vs 36.8%; p=0.02) were higher with A vs E. Overall AE profile was comparable (≥G3 AEs: 50.2 and 49.1%, serious AEs: 39.2 and 38.0% for A and E, respectively) with higher incidence of drug-related ≥G3 diarrhoea (9.7 vs 2.4%) and G3 stomatitis (3.3 vs 0%) with A and higher incidence of G3 rash/acne with E (5.5 vs 9.0%). AEs leading to treatment discontinuation were comparable (17.9 vs 13.9%). More pts had improved global health status/quality of life (36.4 vs 27.1%; p=0.03) with A than E. Changes in mean scores over time significantly favoured A vs E for cough, dyspnoea and pain. Primary OS, updated PFS, response and PRO data will be presented at the meeting. Conclusions: LL8 is the largest prospective trial comparing A vs E, an approved TKI in pts with pretreated SCC. PFS, DCR and improved global health status were significantly better for A than E. AEs were comparable and manageable.
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 8100
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.
8100 Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. The LUX-Lung 8 Phase III global trial compared A and E in pts with SCC of the lung following failure of platinum-based chemotherapy. Between Mar 2012 and Jan 2014, 795 stage IIIB/IV SCC pts were randomized 1:1 to receive A (40 mg/day) or E (150 mg/day) until progression. The primary endpoint of PFS, assessed after 414 events, was significantly higher for A than E (median: 2.4 vs 1.9 months; HR [95% CI]: 0.82 [0.68–1.00]; p = 0.04). PRO analyses of the PFS dataset are presented here. Updated PRO analysis of the OS dataset (to be undertaken after 632 deaths) will be available at the meeting. Methods: PROs were collected every 28 days until progression using the EORTC QLQ-C30/LC13 questionnaires. Percentage of pts improved on therapy, time-to-deterioration (TTD) and changes over time were analyzed for the pre-specified SCC symptoms: cough, dyspnea, and pain. Results: Improveme...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 8100
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.
8100 Background: A is an irreversible ErbB family blocker that has shown clinical activity in pts with SCC of the head/neck and lung. The LUX-Lung 8 Phase III global trial compared A and E in pts with SCC of the lung following failure of platinum-based chemotherapy. Between Mar 2012 and Jan 2014, 795 stage IIIB/IV SCC pts were randomized 1:1 to receive A (40 mg/day) or E (150 mg/day) until progression. The primary endpoint of PFS, assessed after 414 events, was significantly higher for A than E (median: 2.4 vs 1.9 months; HR [95% CI]: 0.82 [0.68–1.00]; p = 0.04). PRO analyses of the PFS dataset are presented here. Updated PRO analysis of the OS dataset (to be undertaken after 632 deaths) will be available at the meeting. Methods: PROs were collected every 28 days until progression using the EORTC QLQ-C30/LC13 questionnaires. Percentage of pts improved on therapy, time-to-deterioration (TTD) and changes over time were analyzed for the pre-specified SCC symptoms: cough, dyspnea, and pain. Results: Improveme...
- Open Access
- 1 January 2015
- Published by Herbert Publications PVT LTD in Pulmonology and Respiratory Research
- Vol. 3 (1) , 4
Vertebral tuberculosis presenting as a posterior mediastinal mass
Vertebral tuberculosis (TB) or Pott's disease has become uncommon since the advent of antituberculosis drugs and improved public health measures. However, it remains a cause of disease, especially in developing countries. It
- 1 January 2015
- Published by Herbert Publications PVT LTD in Pulmonology and Respiratory Research
- Vol. 3 (1) , 4
Open AccessVertebral tuberculosis presenting as a posterior mediastinal mass
Vertebral tuberculosis (TB) or Pott's disease has become uncommon since the advent of antituberculosis drugs and improved public health measures. However, it remains a cause of disease, especially in developing countries. It
- Open Access
- 1 January 2015
- Published by LookUs Bilisim A.S. in Respiratory Case Reports
- Vol. 4 (2) , 96-100
A Rare Cause of Hemoptysis: Goodpasture Syndrome
- 1 January 2015
- Published by LookUs Bilisim A.S. in Respiratory Case Reports
- Vol. 4 (2) , 96-100
Open AccessA Rare Cause of Hemoptysis: Goodpasture Syndrome
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 8046
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).
8046 Background: Pts with NSCLC who are active smokers may have increased erlotinib metabolism v non-smokers, which reduces exposure. Methods: Pts with stage IIIB/IV NSCLC (failed first-line platinum-based chemotherapy, current smokers) were randomized to receive standard dose erlotinib (150 mg/day; E150) or an experimental dose (300 mg/day; E300) until progression/death/unacceptable toxicity. Pts were assessed every 6 wks. Primary endpoint: progression-free survival (PFS). Secondary endpoints included: overall survival (OS), disease control rate (DCR), and safety. Planned sample size: 300 randomized pts; 277 PFS events needed to show a HR of 0.714 (median PFS improvement from 10 to 14 wks; E300 was expected to provide a longer median PFS v E150) with 80% power (5% 2-sided α). Results: Baseline characteristics were balanced (Table). Efficacy and safety results are reported (Table). Conclusions: CurrentS, the first and largest trial in active smokers with NSCLC to date, did not show a statistically signifi...
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 8046
Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).
8046 Background: Pts with NSCLC who are active smokers may have increased erlotinib metabolism v non-smokers, which reduces exposure. Methods: Pts with stage IIIB/IV NSCLC (failed first-line platinum-based chemotherapy, current smokers) were randomized to receive standard dose erlotinib (150 mg/day; E150) or an experimental dose (300 mg/day; E300) until progression/death/unacceptable toxicity. Pts were assessed every 6 wks. Primary endpoint: progression-free survival (PFS). Secondary endpoints included: overall survival (OS), disease control rate (DCR), and safety. Planned sample size: 300 randomized pts; 277 PFS events needed to show a HR of 0.714 (median PFS improvement from 10 to 14 wks; E300 was expected to provide a longer median PFS v E150) with 80% power (5% 2-sided α). Results: Baseline characteristics were balanced (Table). Efficacy and safety results are reported (Table). Conclusions: CurrentS, the first and largest trial in active smokers with NSCLC to date, did not show a statistically signifi...
- Open Access
- 1 January 2014
- Published by LookUs Bilisim A.S. in Respiratory Case Reports
- Vol. 3 (2) , 93-96
A Case of Pulmonary Langerhans Cell Histiocytosis
- 1 January 2014
- Published by LookUs Bilisim A.S. in Respiratory Case Reports
- Vol. 3 (2) , 93-96
Open AccessA Case of Pulmonary Langerhans Cell Histiocytosis
- Open Access
- 1 January 2010
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 30 (4) , 1177-1184
Initial Anthropometric Values and Nutritional Status is Related to Survival in Advanced Non-Small Cell Lung Cancer
- 1 January 2010
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Medical Sciences
- Vol. 30 (4) , 1177-1184
Open AccessInitial Anthropometric Values and Nutritional Status is Related to Survival in Advanced Non-Small Cell Lung Cancer